Sonnet BioTherapeutics Holdings, Inc.

As of February 13, 2025, Sonnet BioTherapeutics Holdings, Inc. is rated as risky and overvalued due to significant financial distress, reflected in its high price-to-book ratio of 3.96 and negative EV to EBIT and EV to EBITDA ratios, alongside a substantial annual loss of 85.84% compared to the S&P 500's 10.26% gain.

As of May 27, 2025, Sonnet BioTherapeutics Holdings, Inc. has a mildly bearish technical outlook, influenced by mixed signals from key indicators like the MACD, Bollinger Bands, RSI, and KST.

As of March 2022, the management team of Sonnet BioTherapeutics Holdings, Inc. is led by Dr. Pankaj Mohan, who is the Chairman, President, and CEO, alongside directors Mr. Nailesh Bhatt, Mr. Albert Dyrness, Mr. Donald Griffith, and Mr. Raghu Rao.

Sonnet BioTherapeutics Holdings, Inc. is an oncology-focused biotechnology company developing targeted biologic drugs. It has a market cap of $3.67 million and reported a net profit loss of $3 million as of March 2025.

As of Jun 18, Sonnet BioTherapeutics Holdings, Inc. has a market capitalization of 3.67 million, with net sales of 1.00 million and a net profit of -13.29 million over the latest four quarters. The company reported shareholder's funds of -0.49 million and total assets of 2.77 million as of Sep 24.